이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Three-Period, Six-Sequence Crossover Study in Healthy Volunteers to Compare the Relative Bioavailability of Itraconazole Tablet (T26) and Itraconazole Capsule (Sporanox®) Under Fed Conditions and to Assess the Food Effect on T26

2026년 11월 16일 업데이트: Triastek, lnc.

This is a phase 1, randomized, open-label, single-center, single-dose, three-period, six-sequence crossover study in healthy adult volunteers. The study is designed to compare the relative bioavailability of itraconazole tablet (T26, Test) with itraconazole capsule (Sporanox®, Reference) under fed conditions; and to assess the food effect from a high-fat meal on T26.

Three treatments, as described below, are planned:

Test Product (Tfed): T26, 130 mg (two 65 mg tablets), administered under fed conditions Reference Product (R): Sporanox®, 200 mg (two 100 mg capsules), administered under fed conditions Test Product (Tfasted): T26, 130 mg (two 65 mg tablets), administered under fasted conditions A total of 18 participants will be randomized 1:1:1:1:1:1 into six different treatment sequences (TfastTfedR, TfastRTfed, TfedTfastR, TfedRTfast, RTfastTfed, RTfedTfast). The dosing between two consecutive treatment periods will be separated by a minimum 14-day washout interval.

This study consists of three periods: a screening period (Day -7~Day -2), a cross-over treatment period, and a safety follow-up visit (Day 36 ~Day 43). During each treatment period, eligible participants will be admitted to the clinical research unit (CRU) one day prior to dosing and will receive a single oral dose of the assigned study treatment on Day 1 according to the randomized sequence. On Day 1 of each treatment period, T26 or Sporanox® will be administered with 240 mL of water at approximately 8:00 a.m. (±1 hour) under fasted or fed condition. Detailed dietary requirements and dosing procedures. Participants will discharge from the CRU on the fifth day of each treatment period after completion of the scheduled safety assessments and collection of the last PK blood sample (up to 96 hours post-dose).

연구 개요

상태

아직 모집하지 않음

연구 유형

중재적

등록 (추정된)

18

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • NA, Municipality
      • Chongqing, NA, Municipality, 중국, 400020
        • No. 1, Jialing Yicun, Liangjiang New Area, Chongqing
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Healthy male and female participants aged 18 years and above (including 18 years).

  2. Male participants with body weight ≥50.0 kg and female participants with body weight ≥45.0 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), within the range of 18.5-30.0 kg/m² (inclusive).

  3. Participants with no history of chronic or serious diseases of the cardiovascular, digestive, urinary, respiratory, hematologic/lymphatic, endocrine, immune, psychiatric, or nervous systems, and in good general health.

  4. Participants must be willing to use effective contraception from screening until 2 months after the last dose of the final treatment cycle.

    a) Female participants must: i. Be of non-child-bearing potential i.e. surgically sterilized or postmenopausal, or ii. If of child-bearing potential, must have a negative pregnancy test at Screening and within 24 hours prior to treatment Day 1. They must agree not to attempt to become pregnant, must not donate ova, and must agree to use two forms of highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug, OR use 1 form of highly effective contraceptive method, plus an additional barrier method of contraception between signing consent, during the study, and at least 2 months after the last dose of study drug.

    iii. Women of childbearing potential (WCBP) with same sex partners who abstain from penile- vaginal intercourse are eligible if such is their preferred and usual lifestyle.

    c) Male participants must: i. Be willing not to donate sperm until at least 2 months after the last dose of study drug and.

    ii. If engaging in sexual intercourse with a female partner who could become pregnant, be willing to use a condom in addition to having the female partner use a highly effective contraceptive method between signing consent, during the study, and at least 2 months after the last dose of study drug.

  5. Voluntarily sign an informed consent form prior to the trial, with full understanding of the trial content, procedures, and potential adverse reactions, and be able to communicate effectively with investigators.

  6. Capable of completing the study in accordance with the trial protocol requirements.

Exclusion Criteria:

  1. Vital signs, physical examination, hearing assessment, laboratory tests (hematology, urinalysis, blood chemistry, coagulation panel), infectious disease panel, 12-lead ECG, etc., showing clinically significant abnormalities;
  2. (Inquiry) Smoking 5 or more cigarettes per day on average within 3 months prior to screening, or unable to refrain from using any tobacco product within 48 h prior to administration and during hospitalization;
  3. (Inquiry) History of acute infectious disease with significant antibiotic use within 3 months before screening, or mild infectious disease within 7 days before first dose;
  4. (Inquiry) History of allergy to itraconazole, other azoles, or any excipients of the investigational product, or allergy to two or more substances;
  5. (Inquiry) Alcohol consumption >14 units per week within 3 months before screening (1 unit = 17.7 mL ethanol, equivalent to ~354 mL of 5% beer, ~44 mL of 40% spirits, or ~147 mL of 12% wine), or unable to abstain from alcohol-containing products during the study, or positive alcohol breath test;
  6. (Inquiry) Received blood transfusion, donated blood, or experienced major blood loss (≥400 mL) within 3 months before first dose;
  7. (Inquiry) Vaccinated within 14 days before first dose, or planning vaccination during the study period;
  8. (Inquiry) Taken any prescription medication, over-the-counter medication, vitamin products, or herbal supplements within 2 weeks before first dose;
  9. (Inquiry) Participants who, within 72 hours prior to the first dose, have consumed special diet (including dragon fruit, mango, grapefruit, etc.), or consumed foods or beverages containing caffeine or rich in xanthine (such as chocolate, strong tea, coffee, cola, animal offal), engaged in vigorous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion;
  10. (Inquiry + System Search) Used other investigational products or participated in clinical drug trials within 3 months before first dose;
  11. Experienced acute illness or required concomitant medication from screening until first dose;
  12. Female participants who are breastfeeding or have a positive pregnancy test results at screening or during the study period;
  13. History of drug abuse within the past year, or illicit drug use within 3 months before screening, or positive drug abuse screening test;
  14. (Inquiry) Dysphagia, lactose intolerance (e.g., history of diarrhea after milk consumption), or inability to comply with standardized diet;
  15. (Inquiry) History of diseases that may affect safety or pharmacokinetics of the investigational product, such as gastric spasms, gastroesophageal reflux disease, Crohn's disease, chronic atrophic gastritis, Sjögren's syndrome, pernicious anemia, etc., or currently having any of these conditions;
  16. (Inquiry) Post-partial gastrectomy, or major surgery within 6 months before screening, or planning surgery during the study, or history of surgery affecting drug absorption, distribution, metabolism, or excretion (except appendectomy);
  17. (Inquiry + System Search) History of serious conditions judged by the investigator as clinically significant in the cardiovascular system (including congestive heart failure, coronary atherosclerotic heart disease, valvular heart disease, arrhythmia, torsades de pointes), hepatic system (active liver disease), urinary system, digestive system, respiratory system (including chronic obstructive pulmonary disease, cystic fibrosis), hematologic/lymphatic system (e.g., neutropenia), nervous system, psychiatric system, visual disorders/abnormalities, auditory disorders (including tinnitus and sudden deafness), malignant tumors, or currently having any of these conditions;
  18. (Inquiry) Use of any drugs known to interact with itraconazole within 4 weeks before screening [including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (e.g., dihydroergotamine, ergometrine, ergotamine, methylergometrine), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin, ticagrelor, levacetylmethadol (levomethadyl), halofantrine, astemizole, mizolastine, terfenadine, sertindole, bepridil, lercanidipine, ivabradine, domperidone, colchicine, fesoterodine, telithromycin, solifenacin, erythromycin, clarithromycin, etc.];
  19. (Inquiry) Female participants who have used long-acting estrogen or progestogen injections or implants within 6 months before the study, or short-acting contraceptives within 30 days before the study;
  20. (Inquiry) History of vasovagal syncope from blood or needles, or unable to tolerate venipuncture;
  21. Participants unable to complete the study due to other reasons;
  22. Participants judged by the investigator to have other factors unsuitable for participation in this study;
  23. Participants with creatinine clearance <80 mL/min (calculated using Cockcroft-Gault formula: CrCl = [(140 - age) × weight (kg)] / [0.818 × serum creatinine (μmol/L)]; for females, multiply result by 0.85);
  24. (Inquiry) Participants with decreased gastric acidity, such as participants taking gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or participants with achlorhydria caused by certain diseases.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Tfasted-Tfed-R group

Test Product

Reference Product

실험적: Tfasted-R-Tfed group

Test Product

Reference Product

실험적: Tfed-Tfasted-R group

Test Product

Reference Product

실험적: Tfed-R-Tfasted group

Test Product

Reference Product

실험적: R-Tfasted-Tfed group

Test Product

Reference Product

실험적: R-Tfed-Tfasted group

Test Product

Reference Product

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Cmax
기간: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-tlast
기간: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose
AUC0-inf
기간: up to 96 hours post-dose

Primary PK parameters

up to 96 hours post-dose

2차 결과 측정

결과 측정
측정값 설명
기간
Tmax
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
t₁/₂
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Kel
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
F
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
CL/F
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
Vz/F
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose
AUC_%Extrap
기간: up to 96 hours post-dose

Secondary PK parameters

up to 96 hours post-dose

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 16일

기본 완료 (추정된)

2026년 12월 19일

연구 완료 (추정된)

2027년 2월 1일

연구 등록 날짜

최초 제출

2026년 11월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다